Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...

The company’s target indications include Alzheimer’s disease, Parkinson’s disease, Rett syndrome, epilepsy, neuropathic pain, depression, prostate cancer, pancreatic cancer infantile spasms, fragile X ...

She cannot attend school before noon, and her school is now under court order to extend her school day until 6 p.m. Ava has had a rare form of epilepsy called Lennox-Gastaut Syndrome since she was ...

More news: Neuren Pharmaceuticals was the worst performing ASX 200 company in early trading after its US partner Acadia Pharmaceuticals applied for approval to market its Rett syndrome treatment, ...

Trofinetide is intended to treat Rett syndrome, a neurodevelopmental disorder. Credit: SewCreamStudio/Shutterstock. Acadia Pharmaceuticals has submitted a marketing ...

Neuren’s partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment of Rett syndrome Compumedics achieves a record $32.8m in sales orders in H1 ...

[15] Inadequate documentation precluded reliable determination of a precise epilepsy syndrome in many patients. If a patient had both partial and generalized seizures, the seizure type was ...

(Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment of Rett syndrome ...

in 18 patients with Rett syndrome (mean age 13.7 years) at clinical stages III and IV. Age at epilepsy onset and seizure frequency were strictly correlated with neuropsychological outcome ...